Controversial ivermectin researcher failed to report massive conflict of interest

Controversial ivermectin researcher failed to report massive conflict of interest

Note that views expressed in this opinion article are the writer’s personal views and not necessarily those of TrialSite.

Susanna Naggie is leading a nation-wide study of ivermectin, ACTIV-6. She is also a member of the NIH panel that provided the current recommendation on the use of ivermectin in COVID-19 that is at odds with the view of leading physicians and experts in evidence-based medicine:

“There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.”

These two positions are in conflict because a recommendation to use ivermectin in COVID-19 is implicitly a recommendation to end the ACTIV-6 trial.

Naggie published “Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19” in Annals of Internal Medicine on June 19, 2021. Like most scientific journals, Annals requires the disclosure ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee